152 related articles for article (PubMed ID: 33715994)
1. Efficacy and safety of inhaled dry-powder mannitol in adults with cystic fibrosis: An international, randomized controlled study.
Flume PA; Amelina E; Daines CL; Charlton B; Leadbetter J; Guasconi A; Aitken ML
J Cyst Fibros; 2021 Nov; 20(6):1003-1009. PubMed ID: 33715994
[TBL] [Abstract][Full Text] [Related]
2. Mannitol dry powder for inhalation: in patients with cystic fibrosis.
Burness CB; Keating GM
Drugs; 2012 Jul; 72(10):1411-21. PubMed ID: 22755516
[TBL] [Abstract][Full Text] [Related]
3. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.
Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B;
Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974
[TBL] [Abstract][Full Text] [Related]
4. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial.
De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A;
J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928
[TBL] [Abstract][Full Text] [Related]
5. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study.
Bilton D; Robinson P; Cooper P; Gallagher CG; Kolbe J; Fox H; Jaques A; Charlton B;
Eur Respir J; 2011 Nov; 38(5):1071-80. PubMed ID: 21478216
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
7. Inhaled mannitol for cystic fibrosis.
Nolan SJ; Thornton J; Murray CS; Dwyer T
Cochrane Database Syst Rev; 2015 Oct; (10):CD008649. PubMed ID: 26451533
[TBL] [Abstract][Full Text] [Related]
8. Inhaled mannitol improves lung function in cystic fibrosis.
Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B
Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790
[TBL] [Abstract][Full Text] [Related]
9. A 12-week, multicenter, randomized, partially blinded, active-controlled, parallel-group study of budesonide inhalation suspension in adolescents and adults with moderate to severe persistent asthma previously receiving inhaled corticosteroids with a metered-dose or dry powder inhaler.
Murphy K; Noonan M; Silkoff PE; Uryniak T
Clin Ther; 2007 Jun; 29(6):1013-26. PubMed ID: 17692718
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma.
LaForce CF; Pearlman DS; Ruff ME; Silvers WS; Weinstein SW; Clements DS; Brown A; Duke S; Harding SM; House KW
Ann Allergy Asthma Immunol; 2000 Nov; 85(5):407-15. PubMed ID: 11101186
[TBL] [Abstract][Full Text] [Related]
11. Comparison of inhaled mannitol/dornase alfa combination and daily dornase alfa alone in children with cystic fibrosis.
Ademhan Tural D; Yalçın E; Emiralioglu N; Ozsezen B; Sunman B; Nayir Buyuksahin H; Guzelkas I; Dogru D; Ozcelik U; Kiper N
Pediatr Pulmonol; 2022 Jan; 57(1):142-151. PubMed ID: 34687284
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ataluren in patients with nonsense-mutation cystic fibrosis not receiving chronic inhaled aminoglycosides: The international, randomized, double-blind, placebo-controlled Ataluren Confirmatory Trial in Cystic Fibrosis (ACT CF).
Konstan MW; VanDevanter DR; Rowe SM; Wilschanski M; Kerem E; Sermet-Gaudelus I; DiMango E; Melotti P; McIntosh J; De Boeck K;
J Cyst Fibros; 2020 Jul; 19(4):595-601. PubMed ID: 31983658
[TBL] [Abstract][Full Text] [Related]
13. Ciprofloxacin Dry Powder for Inhalation: Inspiratory Flow in Patients with Non-cystic Fibrosis Bronchiectasis.
Stass H; Nagelschmitz J; Kappeler D; Sommerer K; Patzlaff A; Weimann B
J Aerosol Med Pulm Drug Deliv; 2019 Jun; 32(3):156-163. PubMed ID: 30848695
[No Abstract] [Full Text] [Related]
14. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
15. A Randomized, Double-Blind, Double-Dummy Study of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Relative to Umeclidinium/Vilanterol Dry Powder Inhaler in COPD.
Maltais F; Ferguson GT; Feldman GJ; Deslee G; Bourdin A; Fjällbrant H; Siwek-Posłuszna A; Jenkins MA; Martin UJ
Adv Ther; 2019 Sep; 36(9):2434-2449. PubMed ID: 31267366
[TBL] [Abstract][Full Text] [Related]
16. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.
Ratjen F; Hug C; Marigowda G; Tian S; Huang X; Stanojevic S; Milla CE; Robinson PD; Waltz D; Davies JC;
Lancet Respir Med; 2017 Jul; 5(7):557-567. PubMed ID: 28606620
[TBL] [Abstract][Full Text] [Related]
18. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
19. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis.
Daviskas E; Anderson SD; Jaques A; Charlton B
Chest; 2010 Apr; 137(4):861-8. PubMed ID: 19880909
[TBL] [Abstract][Full Text] [Related]
20. Inhaled mannitol for non-cystic fibrosis bronchiectasis: a randomised, controlled trial.
Bilton D; Tino G; Barker AF; Chambers DC; De Soyza A; Dupont LJ; O'Dochartaigh C; van Haren EH; Vidal LO; Welte T; Fox HG; Wu J; Charlton B;
Thorax; 2014 Dec; 69(12):1073-9. PubMed ID: 25246664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]